Researchers develop nano-contrast agents for MRI and optical imaging of cancer cells

Researchers from PSG College of Technology, India have developed nano-contrast agents for magnetic resonance imaging (MRI) as well as optical imaging of cancer cells. This report will appear in the forthcoming issue of the journal NANO.

Cancer identification at the early stage remains a challenge to the researchers and clinicians. To diagnose the cancer cells, various imaging modalities are being used. Among these modalities, MRI and optical imaging are combined to develop dual modal imaging. Europium doped gadolinium oxide nanorods were synthesized by co-precipitation technique. Inorder to improve the biocompatibility, the nanoparticles were coated with silica. The invitro cytotoxicity results shows that the developed contrasts are not toxic at the lower concentrations. Invitro MR images reveals that the bright contrasts are produced when the concentration is increased.

According to Dr. R. Arun Kumar, Associate Professor, PSG College of Technology, "The developed nano-contrast serves for both MRI and optical imaging. Therefore, the imaging of cancer with higher sensitivity and spatial resolution is possible. The mortality rate can also be reduced."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elevated blood glucose levels increase early-onset colorectal cancer risk